Mechanistically, inhibition of the PI3K pathway increased AR signaling in PTEN‐deficient prostate cancer in part via relief of negative feedback to HER kinases; conversely, AR antagonism relieves feedback inhibition of AKT by reducing FKBP5‐mediated stability of the phosphatase PHLPP. The gene discussed is AR; the disease is prostate carcinoma.